• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:

    公开号:SE1250158A1
    申请号:SE1250158
    申请日:2012-02-22
    公开日:2013-08-23
    发明作者:Fariba Nayeri；Kamal Bahar
    申请人:Peas Inst Ab；
    IPC主号:
    专利说明:

    In infectious diseases has been shown to be able to demonstrate non-functional therapy at an early stage.
    Insight into the clinical significance and differences between recommended therapies, differential diagnoses between inflammatory conditions in the body have been the subject of several studies. A major clinical problem is to determine whether infection or other inflammatory disorders cause the disease. A number of markers are typically used by physicians to make the correct diagnosis, such as microscope analysis and culture of body fluids, white blood cell count, C-reactive protein, procalcitonin and lactate in plasma. However, there is still no golden standard to use. Problems with making the correct diagnosis arise daily in the treatment of inflammatory disorders of the intestine, ulcers, joint diseases, disorders of the central nervous system, shedding of the peritoneum, alveoli and pericardium, among others. The amount of routine markers such as CRP and white blood cell count can be high in several disorders and cultures are not always positive despite an infection. High levels of HGF and its use in the diagnosis and prognosis of infectious diseases are discussed in FCT application PCT / SE200l / 00 l 83 1.
    In these studies, however, the total amount of HGF in body fluids was determined by ELISA method.
    Various studies on HGF have been reported. Some studies have used the determination of HGF in plasma / serum and urine for the diagnosis and screening of diseases such as acute renal failure, myocardial infarction, bladder cancer, acute pancreatitis and acute and chronic lung diseases. For this reason, previously described methods such as ELISA and Western blotting have been used. Detection of large amounts of cytokines in inflammatory diseases is not a unique finding. However, in some cases, determination of HGF furmits has been a sensitive method that can detect specific clinical problems much more easily than routine methods (FCT application PCT / SE2001 / 00183l).
    Previously described methods such as ELISA and Western blotting are based on an interaction between HGF in the samples and an antibody that binds specifically to HGF. The ELISA determines the amount of single chain and double chain HGF. Western blotting determines the quality of HGF by determining the apparent molecular weights in the sample. However, these methods are cumbersome and labor intensive. 10 15 20 25 The innovative use of biosensors is useful, inexpensive and fast in this area of analysis. The surface plasmon resonance (BIACORE®) method can be used for the detection of HGFi feces (WO2005 / 031365). The technology can detect HGF levels and quality in the same run.
    WO2010 / 151222 describes a method for determining the presence, absence or amount of biologically active or inactive HGF in a sample, comprising contacting the sample with a gel comprising an HGF-binding component from extracellular matrix or cell membranes, adding toluidine blue to the gel, and correlating the color of the gel and / or a liquid in contact with the gel, with the presence, absence or amount of biologically active HGF in the sample.
    -In case of infection: In different organs, the levels of HGF increase locally at the site of infection. The entire amount of protein can be detected by ELISA. With Biacore technology, detection of the level of interaction (signals) of monoclonal, polyclonal antibodies to HGF as well as chip immobilized heparan sulfate proteoglycan (HSPG) is high and correlates positively with the results obtained by ELISA.
    -In the case of chronic inflammation: Despite high amounts of HGF that can be found by ELISA in samples, non-significant correlation is observed between ELISA and results obtained with Biacore. It may be that no or very low signal is detected with Biacore indicating a weak interaction with the ligands. The interaction with the proto-oncogene receptor c-met can be high and the signals correlate positively with the immobilization level. There is a low signal level in the HSPG channel. Addition of HSPG or dextran sulfate to the samples at least 10 minutes before analysis may not reduce the signal in the HSPG channel. The protein may be biologically inactive.
    Method 1 platform) -Under mechanism The growth factors and cytokines as hepatocyte growth factor produced in injury are released endocrine and produced locally by adjacent mesenchymal cells. The protein interacts with the high affinity cell binding specific receptor and sends signals into the cell resulting in regeneration of the damaged organ. In the case of HGF, a non-specific receptor on the cell membrane and the extracellular matrix (ECM) is required to capture the cytokine and make it available to the specific receptor (c-Met receptor). Therefore, variants of HGF that do not show affinity for HSPG or other proteoaminoglycans are not captured by ECM after release and may not interact with the specific receptor. Therefore, the protein may be inactive despite high affinity for the c-Met receptor.
    In our previous work, we have studied HGF with SDS-PAGE, Western blot, ELISA and surface plasmon resonance and shown that the HGF protein (endogenous and recombinant) that did not bind to proteoaminoglycan (HSPG, heparan sulfate) or dextran sulfate, had no biological effect in the in vivo (hair growth mice) or in vitro models (CCL-5 3.1 cells) used in our group. We have seen differences in binding affinities to HSPG in the surface plasmon resonance method for patients with acute infections compared to chronic inflammations. Our primary conclusion is that in patients with chronic breastfeeding, highly hierarchical cytokines such as HGF are inactivated and therefore they may need exogenously biologically active HGF to stimulate regeneration. As an example, treatment with exogenous HGF has been shown to be beneficial in the treatment of certain cases of chronic leg ulcers (PCT application PCT / SE200l / 0183l). HGF has been found to enhance the migration of healthy adjacent skin epithelial cells to the damaged area by altering the skeletal structure of cells in vitro. Elevated expression of the proto-oncogen receptor met (c-met) in the ulcer region in patients with chronic ulcerations is observed. Treatment with exogenous HGF significantly reduced the expression of c-met. There was a negative correlation between concentration of biologically active endogenous HGF in secretions from ulcerations and expression of the proto-oncogene receptor met (c-met). Treatments with exogenous HGF patients with a low amount of endogenous HGF and high expression of the proto-oncogen receptor met (c-met) caused vascular proliferation and reduction of ulceration area. This model of organ damage to the skin and related events may also apply to other organ tissues.
    Summary of the Invention In a first aspect, the present invention relates to a method for detecting the presence or absence of biologically active HGF in a sample, comprising contacting an HGF-containing sample with a porous solid phase having at least one HGF -binding component from extracellular matrix (ECM) or cell membrane, such as a proteoaminoglycan or a glucosaminoglycan, and an indicator composition comprising methyl red, bromothymol blue and a quaternary ammonium compound.
    In a second aspect, the present invention relates to a device comprising a porous solid phase having at least one HGF-binding component from extracellular matrix (ECM) or cell membranes, such as a proteoaminoglycan or a glucosaminoglycan, and an indicator composition comprising methyl red, bromothymol blue and a quaternary ammonium compound.
    Definitions and Abbreviations Quality of HGF indicates the ability of HGF to bind to the extracellular matrix and exert its biological effect in vivo.
    HGF means hepatocyte growth factor, also called Scatter Factor in English.
    ECM means extracellular matrix.
    HSPG means heparan sulfate proteoglycan.
    MQ, or Milli-Q, refers to water that is highly purified and deionized.
    PBS means phosphate buffered saline.
    Detailed Description of the Invention Hepatocyte growth factor in its biologically active form has a high affinity for proteoaminoglycans such as heparan sulfate proteoglycan. and dextran sulfate. This affinity is similar to the binding of growth factor to the cell membrane before interaction with its membrane binding receptor. This affinity is used in the following aspects and embodiments of the present invention.
    Based on previous results with observations from the surface plasmon resonance method which showed that high affinity cytokines to ECM components were released in acute infection, the inventors have prepared a platform by adding proteoaminoglycan in a basic solid matrix, such as cellulose. The affinity for protein for proteoaminoglycan is then visualized with color changes in the presence of indicators including bromothymol blue and a quaternary ammonium compound and / or methyl red.
    The invention uses a cushion phase comprising an HGF-binding component from the extracellular matrix or cell membrane, preferably dextran sulfate or HSPG.
    The pillow is made of a porous solid phase, such as cellulose, nitrocellulose or paper. A presently preferred porous solid phase is a thick cellulose-based filter paper with high loading capacity and average retention filter paper 598 Schleicher & Schull. The following recipe is currently preferred: The porous solid phase is impregnated with a solution of 0.02% methyl red (Merck), 0.4% quaternary ammonium compound (Merck) and 0.1% bromothymol blue (Panreac) in methanol. All chemicals are added to the cellulose matrix by adding 0.5% coating stabilizer (Acros). The papers are dried in a stream of warm air.
    Then, the porous solid phase is soaked for 5 to 10 seconds with a solution composed of 0.1 mM dextran sulfate (F luka) in deionized distilled water (MQ) and dried in a stream of hot air.
    The heat-dried porous solid phase comprising indicator composition proteoaminoglycan can later be fixed on double-sided adhesive paper and immobilized on a solid support, such as a plastic strip, and cut into strips of size suitable for use, such as 6 mm wide. In use, for ease of handling, an amount of feces is transferred to 0.5 ml of dilution buffer (0.1 M PBS pH 7.4) and a test strip comprising a porous solid phase immobilized on a solid support is dipped in the solution. When the test strips are dipped in solution containing HGF, depending on the amount of analyte, it reacts specifically with its conjugate or receptor, for example dextran sulfate. Therefore, the strip changes color from yellow to different observable intensities of green to navy blue.
    The other components of extraoellular matrix (glyco saminoglycans) can be used, but dextran sulfate is cheaper and shows similar results.
    The invention relates to a method comprising dipping a strip in a biological sample or diluted with buffer, preferably PBS 0.5 M to 0.15 M, pH 6.00 ~ 8.00, wherein biologically active HGF binds to dextran sulfate.
    Remaining drops of sample on the edges of the strip are removed by gently tapping on blotting paper. Interaction between dextran sulfate and indicator changes the color of the pillow from yellow to a spectrum of green to dark blue as a positive signal for the presence of HGF.
    There is a specific interaction between biologically active HGF and dextran sulfate in the presence of indicators in the porous solid phase medium. Because the sample contains biologically active HGF that binds to dextran sulfate, the color of the porous solid phase changes. the intensity of the green color depends on the affinity of HGF for dextran sulphate and blocking H1 ions in the porous solid phase.
    The amount of HGF, as observed intensity of green color in the porous solid phase, can be determined by ferrous measurement of HGF using a standard method, for example a quantitative ELISA method. One or more reference solutions with known HGF content are optionally used to evaluate the reaction result. A negative reference can be used (for example water or PBS). A positive reference can be a sample of healthy body fluid or an HGF-containing product with known HGF content.
    By the method according to the invention it is possible to quickly distinguish between an acute infection such as a bacterial infection in an organ from a chronic inflammation.
    The methods and products can be used to analyze the following: - Differences between septic arthritis and non-septic or reactive arthritis in joints - Differences between acute infectious gastritis and chronic intestinal intestinal disease and other causes of diarrhea - Differences between acute septic meningitis and non-specific pleural effusion in cerebrospinal fluid - Differences between acute renal failure as well as pyelonephritis and distal urinary tract infection as well as chronic kidney damage - Differences between pneumonia and chronic obstructive pulmonary disease in condensed exhaled air - Differences between septic inhalation in asymptomatic - Standard evaluation of biologically active HGF in medicines and blood products - Monitoring of treatment with antibiotics - Location of infectious focus in disease
    权利要求:
    Claims (1)
    [1]
    1. 0 15 20 25 30 PATENT REQUIREMENTS. A method for determining the presence, absence or amount of biologically active HGF in a sample, comprising the steps of - contacting the sample with a porous solid phase comprising an HGF-binding component from extracellular matrix (ECM) or cell membrane, and an indicator composition comprising bromothymol blue , a quaternary ammonium compound, and methyl red, - correlate the color of the porous solid phase with the presence, absence or amount of biologically active HGF in the sample. . A device comprising a porous solid phase comprising at least one HGF-binding component from extracellular matrix (ECM) or cell membrane, and an indicator composition comprising bromothymol blue, a quaternary ammonium compound, and methyl red. . A method according to claim 1 wherein the HGF-binding component is a proteoaminoglycan or glycosaminoglycan. . A method according to claim 3, wherein the HGF-binding component is heparan sulphate proteoglycan or dextran sulphate. . A method according to any one of claims 1, 3 or 4, wherein said sample is a tissue, body fluid or excrement from a patient. . A method according to any one of claims 1, 3-5, wherein said sample is a pharmaceutical product. . A method according to any one of claims 1, 3-6, wherein the correlation of the color of the porous solid phase with the presence, absence or amount of biologically active HGF in the sample includes a comparison of the color of the porous solid phase with a porous solid phase which has been brought in contact with at least one reference solution with known HGF content. A device according to claim 2, wherein the HGF-binding component is a proteoaminoglycan or glycosaminoglycan. A device according to claim 8, wherein the HGF-binding component is heparan sulphate proteoglycan or dextran sulphate. A device according to any one of claims 2, 8 or 9, wherein the porous solid phase comprises cellulose. 10
    类似技术:
    公开号 | 公开日 | 专利标题
    Shozushima et al.2011|Usefulness of presepsin | measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome
    Ekman et al.2010|Plasma concentrations of Gas6 | and its soluble tyrosine kinase receptor sAxl in sepsis and systemic inflammatory response syndromes
    Silva-Ramos et al.2013|Urinary ATP may be a dynamic biomarker of detrusor overactivity in women with overactive bladder syndrome
    Irie et al.2012|Levels of the oxidative stress marker γ-glutamyltranspeptidase at different stages of nonalcoholic fatty liver disease
    US11041864B2|2021-06-22|Method for prediction of prognosis of sepsis
    Liao et al.2009|Triggering receptor in myeloid cells | specific expression in peripheral blood mononuclear cells of sepsis patients with acute cholangitis
    JP2010521694A|2010-06-24|Diagnostic tests for kidney injury
    Krzystek-Korpacka et al.2009|Clinical relevance of circulating midkine in ulcerative colitis
    Yu et al.2016|Distinction between bacterial and viral infections by serum measurement of human neutrophil lipocalin | and the impact of antibody selection
    Zhang et al.2005|APF, HB-EGF, and EGF biomarkers in patients with ulcerative vs. non-ulcerative interstitial cystitis
    RU2445915C1|2012-03-27|Method for prediction of risk of decreasing body resistance to acute respiratory diseases in children between ages of 3 to 7 by secretory immunoglobulin a avidity index
    US9157920B2|2015-10-13|Method for determining biologically active HGF
    SE1250158A1|2013-08-23|New method for rapid detection of hepatocyte growth factor in biological fluids
    CN108956998A|2018-12-07|A kind of heparin-binding protein assay kit and measuring method using immunofluorescence dry type quantitative method
    Chang et al.2015|Intra-abdominal hypertension does not predict renal recovery or in-hospital mortality in critically ill patients with acute kidney injury
    CN206772987U|2017-12-19|A kind of multi objective time-resolved fluoroimmunoassay for acute injury of kidney Quantitative detection chromatographs kit
    CN206772986U|2017-12-19|A kind of multi objective Quantitative detection colloidal gold kit for renal failure detection
    RU2634262C1|2017-10-24|Method for determination of indications for selective adsorption of endotoxin in patients with sepsis caused by gram-negativemicroorganisms
    RU2734670C1|2020-10-21|Diagnostic technique for complications of viral and bacterial aetiology in patients with chronic lymphatic leukemia
    JP6456965B2|2019-01-23|Method for assessing mortality risk in patients with systemic inflammatory response syndrome | or sepsis
    CN202676704U|2013-01-16|Test strip used for detecting NGAL | colloidal gold
    Ashour et al.2019|Serum and ascitic fluid high sensitive C reactive protein as prognostic marker in patients with spontaneous bacterial peritonitis
    CN103698533A|2014-04-02|Use of Apo-Al protein in preparation of serum marker for early screening or diagnosis of lung cancer
    CN109596836A|2019-04-09|A kind of LBP checkout and diagnosis reagent detection system and method
    Abdelrahman et al.2015|The diagnostic value of serum level of soluble hemoglobin scavenger receptor CD163 for sepsis in the ICU
    同族专利:
    公开号 | 公开日
    EP2817636A1|2014-12-31|
    US9435815B2|2016-09-06|
    WO2013126013A1|2013-08-29|
    EP2817636A4|2015-08-19|
    CN104246509A|2014-12-24|
    CN104246509B|2017-10-24|
    SE536400C2|2013-10-08|
    EP2817636B1|2019-02-20|
    US20150037908A1|2015-02-05|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US5183742A|1984-02-24|1993-02-02|Dai Nippon Insatsu Kabushiki Kaisha|Test device for detecting glucose, protein urobilinogen, and/or occult blood in body fluids and/or determining the PH thereof|
    US5656443A|1994-07-29|1997-08-12|Long Island Jewish Medical Center|Method of diagnosing bladder cancer|
    US5827673A|1996-08-13|1998-10-27|Akira Matsumori|Method of detecting myocardial infarction|
    US5660790A|1996-08-13|1997-08-26|Litmus Concepts, Inc.|PH and amine test elements|
    EP1867996A1|2000-08-28|2007-12-19|Damavand Wound AB|Kit for determining HGF in excrement|
    DK1687636T3|2003-09-29|2009-05-11|Peas Inst Ab|Rapid determination of various forms of hepatocyte growth factor in body fluids|
    WO2010151222A1|2009-06-26|2010-12-29|Fariba Nayeri|Method for determining biologically active hgf|
    EP2504705B1|2009-11-27|2017-04-12|Roche Diagnostics GmbH|Method for diagnosing and monitoring cardiac ischemia in patients with acute chest pain and without myocardial infarction|WO2018078184A1|2016-10-31|2018-05-03|Peas Institut Ab|Device and method for detecting a bacterial infection|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    SE1250158A|SE536400C2|2012-02-22|2012-02-22|New method for rapid detection of hepatocyte growth factor in biological fluids|SE1250158A| SE536400C2|2012-02-22|2012-02-22|New method for rapid detection of hepatocyte growth factor in biological fluids|
    EP13751847.8A| EP2817636B1|2012-02-22|2013-02-22|New method for rapid detection of hepatocyte growth factor in biological fluids|
    US14/380,153| US9435815B2|2012-02-22|2013-02-22|Method for rapid detection of hepatocyte growth factor in biological fluids|
    CN201380014381.2A| CN104246509B|2012-02-22|2013-02-22|The new method of HGF in quick detection biofluid|
    PCT/SE2013/050157| WO2013126013A1|2012-02-22|2013-02-22|New method for rapid detection of hepatocyte growth factor in biological fluids|
    [返回顶部]